Baseimmune secured $4.8 million in a round led by Hoxton Ventures

Baseimmune, an Oxford, UK-based biotech company, announced the completion of a $4.8 million funding round.

The money was raised from investors led by Hoxton Ventures along with participation from early round lead investors Creator Fund, along with Cherry Ventures from Germany, Beast Ventures from the UK, Maki.VC from Finland and Rockmount Seed Investments from Jersey

The proceeds of this round will help the company grow, develop more vaccines in parallel and further expanding the number of diseases it is able to tackle.

Baseimmune, founded in 2019 by a group of Oxford University scientists led by CEO Ariane Gomes, is using artificial intelligence (AI) and big data to predict how viruses will change, and to identify “future-proof” antigens that will form key elements of the next generation of vaccines. As well as COVID, it is designing vaccines for malaria, HPV and others. Baseissume revealed that it is working on the world’s first multi genotypes therapeutic vaccine against HPV, designed to prevent those infected from developing cervical cancer. Recently, the Baseimmune partnered with DNA vaccine pioneers Touchlight to develop a universal coronavirus vaccine aimed at tackling the emergence of new variants and preventing future pandemics. Also, the team fed the small amount of existing data about SARS-CoV-2 into their algorithm, which correctly predicted major variants such as Alpha and Delta that would not emerge for another year.

Prior to this round, Baseimmune raised £685k earlier in 2021.